Tags

Type your tag names separated by a space and hit enter

Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
Am J Hematol. 2020 08; 95(8):E192-E194.AJ

Authors+Show Affiliations

Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.Pediatric Intensive Care Unit, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.Imaging Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

32358817

Citation

Odièvre, Marie-Hélène, et al. "Dramatic Improvement After Tocilizumab of Severe COVID-19 in a Child With Sickle Cell Disease and Acute Chest Syndrome." American Journal of Hematology, vol. 95, no. 8, 2020, pp. E192-E194.
Odièvre MH, de Marcellus C, Ducou Le Pointe H, et al. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Am J Hematol. 2020;95(8):E192-E194.
Odièvre, M. H., de Marcellus, C., Ducou Le Pointe, H., Allali, S., Romain, A. S., Youn, J., Taytard, J., Nathan, N., & Corvol, H. (2020). Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. American Journal of Hematology, 95(8), E192-E194. https://doi.org/10.1002/ajh.25855
Odièvre MH, et al. Dramatic Improvement After Tocilizumab of Severe COVID-19 in a Child With Sickle Cell Disease and Acute Chest Syndrome. Am J Hematol. 2020;95(8):E192-E194. PubMed PMID: 32358817.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. AU - Odièvre,Marie-Hélène, AU - de Marcellus,Charles, AU - Ducou Le Pointe,Hubert, AU - Allali,Slimane, AU - Romain,Anne-Sophie, AU - Youn,Jenny, AU - Taytard,Jessica, AU - Nathan,Nadia, AU - Corvol,Harriet, Y1 - 2020/05/16/ PY - 2020/04/21/received PY - 2020/04/27/revised PY - 2020/04/27/accepted PY - 2020/5/3/pubmed PY - 2020/7/21/medline PY - 2020/5/3/entrez SP - E192 EP - E194 JF - American journal of hematology JO - Am J Hematol VL - 95 IS - 8 SN - 1096-8652 UR - https://www.unboundmedicine.com/medline/citation/32358817/Dramatic_improvement_after_tocilizumab_of_severe_COVID_19_in_a_child_with_sickle_cell_disease_and_acute_chest_syndrome_ L2 - https://doi.org/10.1002/ajh.25855 DB - PRIME DP - Unbound Medicine ER -